Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.
Johnson MG, Liu JJ, Li AR, van Lengerich B, Wang S, Medina JC, Collins TL, Danao J, Seitz L, Willee A, D'Souza W, Budelsky AL, Fan PW, Wong SG. Johnson MG, et al. Among authors: seitz l. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2877-80. doi: 10.1016/j.bmcl.2014.04.092. Epub 2014 May 4. Bioorg Med Chem Lett. 2014. PMID: 24825301
Discovery and optimization of CRTH2 and DP dual antagonists.
Liu J, Fu Z, Wang Y, Schmitt M, Huang A, Marshall D, Tonn G, Seitz L, Sullivan T, Lucy Tang H, Collins T, Medina J. Liu J, et al. Among authors: seitz l. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6419-23. doi: 10.1016/j.bmcl.2009.09.052. Epub 2009 Sep 17. Bioorg Med Chem Lett. 2009. PMID: 19804971
Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists.
Liu JJ, Wang Y, Johnson MG, Li AR, Shen W, Wang X, Su Y, Brown M, Van Lengerich B, Rickel E, Martin T, Budelsky A, Seitz L, Danao J, Tang HL, Collins T, Medina JC. Liu JJ, et al. Among authors: seitz l. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1686-9. doi: 10.1016/j.bmcl.2011.12.107. Epub 2011 Dec 30. Bioorg Med Chem Lett. 2012. PMID: 22264478
Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.
Liu J, Li AR, Wang Y, Johnson MG, Su Y, Shen W, Wang X, Lively S, Brown M, Lai S, Gonzalez Lopez De Turiso F, Xu Q, Van Lengerich B, Schmitt M, Fu Z, Sun Y, Lawlis S, Seitz L, Danao J, Wait J, Ye Q, Tang HL, Grillo M, Collins TL, Sullivan TJ, Medina JC. Liu J, et al. Among authors: seitz l. ACS Med Chem Lett. 2011 Mar 2;2(5):326-30. doi: 10.1021/ml1002234. eCollection 2011 May 12. ACS Med Chem Lett. 2011. PMID: 24900313 Free PMC article.
Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.
Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, Ertl LS, Zeng Y, Powers JP, Pennell AM, Bekker P, Schall TJ, Jaen JC. Dairaghi DJ, et al. Among authors: seitz lc. Clin Pharmacol Ther. 2011 May;89(5):726-34. doi: 10.1038/clpt.2011.33. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451509 Clinical Trial.
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications.
Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou CL, Charo IF, Bekker P, Schall TJ, Jaen JC. Sullivan TJ, et al. Among authors: seitz l. J Pharmacol Exp Ther. 2012 Jun 5. doi: 10.1124/jpet.111.190918. Epub 2012 Jun 5. J Pharmacol Exp Ther. 2012. Retraction in: J Pharmacol Exp Ther. 2012 Jul;342(1):234. PMID: 22378937 Retracted.
The following manuscript was published as a Fast Forward article on February 29, 2012: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y, Zhao BN, Baumgart T, Berahovich R, Ertl LS, Pennell A, Seitz L, Miao S, Ungashe S, Wei Z, Johnson D, Boring L, Tsou C …
The following manuscript was published as a Fast Forward article on February 29, 2012: Sullivan TJ, Dairaghi DJ, Krasinski A, Miao Z, Wang Y …
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ. Bekker P, et al. Among authors: seitz l. PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016. PLoS One. 2016. PMID: 27768695 Free PMC article. Clinical Trial.
C5a receptor (CD88) blockade protects against MPO-ANCA GN.
Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC. Xiao H, et al. Among authors: seitz lc. J Am Soc Nephrol. 2014 Feb;25(2):225-31. doi: 10.1681/ASN.2013020143. Epub 2013 Oct 31. J Am Soc Nephrol. 2014. PMID: 24179165 Free PMC article.
151 results